Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF

Key Points

• Weight loss significantly enhances the benefits of tirzepatide in heart failure with preserved ejection fraction (HFpEF).
• Central adiposity measured as waist circumference correlates positively with response to tirzepatide treatment.
• Analysis highlights the importance of body mass index in determining patient outcomes after weight loss interventions.
• These findings may suggest a personalized approach for improving therapy efficacy in HFpEF patients.